Overall Score

Financial Health

Liquidity is only adequate with a current ratio of 1.03 and cash ratio of 0.51, leaving limited cushion.

Leverage remains low with debt-to-equity at 0.06 and debt-to-assets at 0.03.

Cash generation is positive, with operating cash flow of $0.90/share and free cash flow of $0.86/share, but profitability remains negative.

Profitability

Gross margin is strong at 77.4%, but operating margin remains negative at -5.8%.

Return metrics are still weak, with ROE at -14.0% and ROIC at -9.7%.

Negative net margin of -6.1% indicates the business is not yet consistently profitable.

Valuation

The stock trades at a modest 1.19x sales and 10.98x free cash flow, which is not demanding if cash flow holds.

Negative earnings and EBITDA make earnings-based valuation less useful right now.

Price-to-book of 2.51x suggests the market is still assigning some value to the asset base despite weak profitability.

Operational Efficiency

Asset turnover is solid at 0.92x and fixed asset turnover is very high at 48.3x.

Working capital remains tight, with a current ratio just above 1.0.

The cash conversion cycle is positive at 23.2 days, indicating cash is tied up for a short period.

Growth Execution

Revenue per share of $8.00 supports a reasonable top-line base.

High SG&A at 61.1% of revenue and R&D at 22.2% of revenue continue to pressure margins.

Stock-based compensation remains elevated at 15.1% of revenue, which can dilute shareholder returns.